BACKGROUND: The majority of patients in need of a hematopoietic-cell transplant do not have a matched related donor. Data are needed to inform the choice among various alternative donor-cell sources. METHODS: In this retrospective analysis, we compared outcomes in 582 consecutive patients with acute leukemia or the myelodysplastic syndrome who received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blood donor (140 patients), an HLA-matched unrelated donor (344), or an HLA-mismatched unrelated donor (98). RESULTS: The relative risks of death and relapse between the cord-blood group and the two other unrelated-donor groups appeared to vary according to the presence of minimal residual disease status before transplantation. Among patients with minimal residual disease, the risk of death was higher in the HLA-mismatched group than in the cord-blood group (hazard ratio, 2.92; 95% confidence interval [CI], 1.52 to 5.63; P=0.001); the risk was also higher in the HLA-matched group than in the cord-blood group but not significantly so (hazard ratio, 1.69; 95% CI, 0.94 to 3.02; P=0.08). Among patients without minimal residual disease, the hazard ratios were lower (hazard ratio in the HLA-mismatched group, 1.36; 95% CI, 0.76 to 2.46; P=0.30; hazard ratio in the HLA-matched group, 0.78; 95% CI, 0.48 to 1.28; P=0.33). The risk of relapse among patients with minimal residual disease was significantly higher in the two unrelated-donor groups than in the cord-blood group (hazard ratio in the HLA-mismatched group, 3.01; 95% CI, 1.22 to 7.38; P=0.02; hazard ratio in the HLA-matched group, 2.92; 95% CI, 1.34 to 6.35; P=0.007). Among patients without minimal residual disease, the magnitude of these associations was lower (hazard ratio in the HLA-mismatched group, 1.28; 95% CI, 0.51 to 3.25; P=0.60; hazard ratio in the HLA-matched group, 1.30; 95% CI, 0.65 to 2.58; P=0.46). CONCLUSIONS: Our data suggest that among patients with pretransplantation minimal residual disease, the probability of overall survival after receipt of a transplant from a cord-blood donor was at least as favorable as that after receipt of a transplant from an HLA-matched unrelated donor and was significantly higher than the probability after receipt of a transplant from an HLA-mismatched unrelated donor. Furthermore, the probability of relapse was lower in the cord-blood group than in either of the other groups.
BACKGROUND: The majority of patients in need of a hematopoietic-cell transplant do not have a matched related donor. Data are needed to inform the choice among various alternative donor-cell sources. METHODS: In this retrospective analysis, we compared outcomes in 582 consecutive patients with acute leukemia or the myelodysplastic syndrome who received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blood donor (140 patients), an HLA-matched unrelated donor (344), or an HLA-mismatched unrelated donor (98). RESULTS: The relative risks of death and relapse between the cord-blood group and the two other unrelated-donor groups appeared to vary according to the presence of minimal residual disease status before transplantation. Among patients with minimal residual disease, the risk of death was higher in the HLA-mismatched group than in the cord-blood group (hazard ratio, 2.92; 95% confidence interval [CI], 1.52 to 5.63; P=0.001); the risk was also higher in the HLA-matched group than in the cord-blood group but not significantly so (hazard ratio, 1.69; 95% CI, 0.94 to 3.02; P=0.08). Among patients without minimal residual disease, the hazard ratios were lower (hazard ratio in the HLA-mismatched group, 1.36; 95% CI, 0.76 to 2.46; P=0.30; hazard ratio in the HLA-matched group, 0.78; 95% CI, 0.48 to 1.28; P=0.33). The risk of relapse among patients with minimal residual disease was significantly higher in the two unrelated-donor groups than in the cord-blood group (hazard ratio in the HLA-mismatched group, 3.01; 95% CI, 1.22 to 7.38; P=0.02; hazard ratio in the HLA-matched group, 2.92; 95% CI, 1.34 to 6.35; P=0.007). Among patients without minimal residual disease, the magnitude of these associations was lower (hazard ratio in the HLA-mismatched group, 1.28; 95% CI, 0.51 to 3.25; P=0.60; hazard ratio in the HLA-matched group, 1.30; 95% CI, 0.65 to 2.58; P=0.46). CONCLUSIONS: Our data suggest that among patients with pretransplantation minimal residual disease, the probability of overall survival after receipt of a transplant from a cord-blood donor was at least as favorable as that after receipt of a transplant from an HLA-matched unrelated donor and was significantly higher than the probability after receipt of a transplant from an HLA-mismatched unrelated donor. Furthermore, the probability of relapse was lower in the cord-blood group than in either of the other groups.
Authors: J Kurtzberg; M Laughlin; M L Graham; C Smith; J F Olson; E C Halperin; G Ciocci; C Carrier; C E Stevens; P Rubinstein Journal: N Engl J Med Date: 1996-07-18 Impact factor: 91.245
Authors: Marcos de Lima; Ian McNiece; Simon N Robinson; Mark Munsell; Mary Eapen; Mary Horowitz; Amin Alousi; Rima Saliba; John D McMannis; Indreshpal Kaur; Partow Kebriaei; Simrit Parmar; Uday Popat; Chitra Hosing; Richard Champlin; Catherine Bollard; Jeffrey J Molldrem; Roy B Jones; Yago Nieto; Borje S Andersson; Nina Shah; Betul Oran; Laurence J N Cooper; Laura Worth; Muzaffar H Qazilbash; Martin Korbling; Gabriela Rondon; Stefan Ciurea; Doyle Bosque; Ila Maewal; Paul J Simmons; Elizabeth J Shpall Journal: N Engl J Med Date: 2012-12-13 Impact factor: 91.245
Authors: David I Marks; Kwang Ahn Woo; Xiaobo Zhong; Frederick R Appelbaum; Veronika Bachanova; Juliet N Barker; Claudio G Brunstein; John Gibson; Partow Kebriaei; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Joseph Pidala; Bipin Savani; Vanderson Rocha; Mary Eapen Journal: Haematologica Date: 2013-09-20 Impact factor: 9.941
Authors: A Ruggeri; G Michel; J-H Dalle; M Caniglia; F Locatelli; A Campos; C D de Heredia; M Mohty; J M P Hurtado; M Bierings; H Bittencourt; M Mauad; D Purtill; R Cunha; N Kabbara; E Gluckman; M Labopin; C Peters; V Rocha Journal: Leukemia Date: 2012-05-04 Impact factor: 11.528
Authors: Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman Journal: N Engl J Med Date: 2004-11-25 Impact factor: 91.245
Authors: Colleen Delaney; Shelly Heimfeld; Carolyn Brashem-Stein; Howard Voorhies; Ronald L Manger; Irwin D Bernstein Journal: Nat Med Date: 2010-01-17 Impact factor: 53.440
Authors: Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer Journal: N Engl J Med Date: 2012-10-18 Impact factor: 91.245
Authors: Loren Gragert; Mary Eapen; Eric Williams; John Freeman; Stephen Spellman; Robert Baitty; Robert Hartzman; J Douglas Rizzo; Mary Horowitz; Dennis Confer; Martin Maiers Journal: N Engl J Med Date: 2014-07-24 Impact factor: 91.245
Authors: Mary Eapen; Pablo Rubinstein; Mei-Jie Zhang; Cladd Stevens; Joanne Kurtzberg; Andromachi Scaradavou; Fausto R Loberiza; Richard E Champlin; John P Klein; Mary M Horowitz; John E Wagner Journal: Lancet Date: 2007-06-09 Impact factor: 79.321
Authors: Sami B Kanaan; Hilary S Gammill; Whitney E Harrington; Stephen C De Rosa; Philip A Stevenson; Alexandra M Forsyth; Judy Allen; Emma Cousin; Koen van Besien; Colleen S Delaney; J Lee Nelson Journal: Oncoimmunology Date: 2017-03-31 Impact factor: 8.110
Authors: Mahmoud Elsawy; Barry E Storer; Filippo Milano; Brenda M Sandmaier; Colleen Delaney; Rachel B Salit; Ahmed H Rashad; Ann E Woolfrey; Frederick R Appelbaum; Rainer Storb; Mohamed L Sorror Journal: Biol Blood Marrow Transplant Date: 2018-11-28 Impact factor: 5.742